Ignite Creation Date:
2025-12-25 @ 3:29 AM
Ignite Modification Date:
2025-12-26 @ 2:10 AM
Study NCT ID:
NCT01769105
Status:
COMPLETED
Last Update Posted:
2014-10-07
First Post:
2013-01-11
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Comparison of Lipiflow®-Treatment and a Standard Lid Hygiene Regime
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000080343', 'term': 'Meibomian Gland Dysfunction'}], 'ancestors': [{'id': 'D005141', 'term': 'Eyelid Diseases'}, {'id': 'D005128', 'term': 'Eye Diseases'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'David.Finis@med.uni-duesseldorf.de', 'phone': '+49 211 8117320', 'title': 'Dr. David Finis', 'organization': 'Department of ophthalmology, University of Duesseldorf'}, 'certainAgreement': {'piSponsorEmployee': True}, 'limitationsAndCaveats': {'description': 'For further information please have a look at Finis et al: Evaluation of an automated thermodynamic treatment (LipiFlow®) system for meibomian gland dysfunction: a prospective, randomized, observer-masked trial.Ocul Surf. 2014 Apr;12(2):146-54.'}}, 'adverseEventsModule': {'timeFrame': '3 month', 'eventGroups': [{'id': 'EG000', 'title': 'Standard Lid Hygiene Regime First, Then Lipiflow', 'description': 'Patients receive detailed verbal and written instruction to perform lid hygiene twice daily first and then Lipiflow\n\nLid hygiene regime: Patients receive verbal and written instruction to perform lid hygiene twice daily and after 3 month a single Lipiflow-treatment', 'otherNumAtRisk': 16, 'otherNumAffected': 0, 'seriousNumAtRisk': 16, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Lipiflow', 'description': 'Patients receive a singe Lipiflow-treatment\n\nLipiflow: Patients receive a single Lipiflow-treatment', 'otherNumAtRisk': 19, 'otherNumAffected': 0, 'seriousNumAtRisk': 19, 'seriousNumAffected': 0}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Change of Dry Eye Symptoms', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '17', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Standard Lid Hygiene Regime', 'description': 'Patients receive detailed verbal and written instruction to perform lid hygiene twice daily\n\nLid hygiene regime: Patients receive verbal and written instruction to perform lid hygiene twice daily'}, {'id': 'OG001', 'title': 'Lipiflow', 'description': 'Patients receive a singe Lipiflow-treatment\n\nLipiflow: Patients receive a single Lipiflow-treatment'}, {'id': 'OG002', 'title': 'Cross-over Lipiflow', 'description': 'patients received a single Lipiflow treatment after performing lid hygiene for 3 month'}], 'classes': [{'title': 'OSDI Baseline', 'categories': [{'measurements': [{'value': '40.1', 'spread': '16.7', 'groupId': 'OG000'}, {'value': '46.2', 'spread': '14.8', 'groupId': 'OG001'}, {'value': '39.7', 'spread': '23.6', 'groupId': 'OG002'}]}]}, {'title': 'SPEED Baseline', 'categories': [{'measurements': [{'value': '15.9', 'spread': '6.6', 'groupId': 'OG000'}, {'value': '16.8', 'spread': '5.6', 'groupId': 'OG001'}, {'value': '14.7', 'spread': '7.7', 'groupId': 'OG002'}]}]}, {'title': 'OSDI 3 month', 'categories': [{'measurements': [{'value': '40.0', 'spread': '23.4', 'groupId': 'OG000'}, {'value': '34.6', 'spread': '19.6', 'groupId': 'OG001'}, {'value': '32.8', 'spread': '24.4', 'groupId': 'OG002'}]}]}, {'title': 'SPEED 3 month', 'categories': [{'measurements': [{'value': '14.7', 'spread': '7.1', 'groupId': 'OG000'}, {'value': '14.5', 'spread': '7.2', 'groupId': 'OG001'}, {'value': '12.6', 'spread': '6.5', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'after 3 month compared to baseline value', 'description': 'The symptoms of dry eyes are measured in our study with the OSDI and the SPEED questionaire. Primary outcome measure (OSDI)\n\nPatients completed two symptom questionnaires: OSDI (Ocular Surface Disease Index) and SPEED (Standard Patient Evaluation of Eye dryness).\n\nOSDI scores range from 0 (no symptoms) to 100 (severe symptoms). SPEED scores range from 0 (no symptoms) to 28 (severe symptoms). So a reduction of the OSDI or SPEED score indicates an improvement of subjective dry eye symptoms.', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation'}, {'type': 'SECONDARY', 'title': 'Change of Break-up-time', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '17', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Standard Lid Hygiene Regime', 'description': 'Patients receive detailed verbal and written instruction to perform lid hygiene twice daily\n\nLid hygiene regime: Patients receive verbal and written instruction to perform lid hygiene twice daily'}, {'id': 'OG001', 'title': 'Lipiflow', 'description': 'Patients receive a singe Lipiflow-treatment\n\nLipiflow: Patients receive a single Lipiflow-treatment'}, {'id': 'OG002', 'title': 'Cross-over Lipiflow', 'description': 'Patients receive Lipiflow after performing Lid hygiene for 3 month'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '7.7', 'spread': '6.1', 'groupId': 'OG000'}, {'value': '7.9', 'spread': '8.5', 'groupId': 'OG001'}, {'value': '6.7', 'spread': '6.1', 'groupId': 'OG002'}]}]}, {'title': 'After 3 month', 'categories': [{'measurements': [{'value': '7.5', 'spread': '6.1', 'groupId': 'OG000'}, {'value': '9.9', 'spread': '7.0', 'groupId': 'OG001'}, {'value': '7.3', 'spread': '5.1', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'after 3 month compared to baseline value', 'description': 'break-up-time is measured non-invasive with the Oculus Keratograph 5 M;\n\nThe break-up-time is measured in seconds. A low break-up-time suggests a lower lipid layer thickness. A higher break-up-time can be regarded as an improvement of ocular surface lubrication.', 'unitOfMeasure': 'seconds', 'dispersionType': 'Standard Deviation'}, {'type': 'SECONDARY', 'title': 'Change in Tear Film Osmolarity', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '17', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Standard Lid Hygiene Regime', 'description': 'Patients receive detailed verbal and written instruction to perform lid hygiene twice daily\n\nLid hygiene regime: Patients receive verbal and written instruction to perform lid hygiene twice daily'}, {'id': 'OG001', 'title': 'Lipiflow', 'description': 'Patients receive a singe Lipiflow-treatment\n\nLipiflow: Patients receive a single Lipiflow-treatment'}, {'id': 'OG002', 'title': 'Cross-over Lipiflow', 'description': 'Patients receive Lipiflow after performing Lid hygiene for 3 month'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '296.7', 'spread': '10.2', 'groupId': 'OG000'}, {'value': '301.5', 'spread': '11.4', 'groupId': 'OG001'}, {'value': '305.0', 'spread': '8.7', 'groupId': 'OG002'}]}]}, {'title': 'After 3 month', 'categories': [{'measurements': [{'value': '303.7', 'spread': '8.1', 'groupId': 'OG000'}, {'value': '307.1', 'spread': '14.0', 'groupId': 'OG001'}, {'value': '310.0', 'spread': '7.4', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'after 3 month compared to baseline value', 'description': 'osmolarity is measured with the tear-lab;\n\nThe osmolarity is measured in mOsm/l. A higher osmolarity can be regarded as an objective sign of dry eye disease.\n\nA lower osmolarity after therapy can be regarded as an improvement of ocular surface disease.', 'unitOfMeasure': 'mOsm/L', 'dispersionType': 'Standard Deviation'}, {'type': 'SECONDARY', 'title': 'Change in Lipid Layer Thickness', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '17', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Standard Lid Hygiene Regime', 'description': 'Patients receive detailed verbal and written instruction to perform lid hygiene twice daily\n\nLid hygiene regime: Patients receive verbal and written instruction to perform lid hygiene twice daily'}, {'id': 'OG001', 'title': 'Lipiflow', 'description': 'Patients receive a singe Lipiflow-treatment\n\nLipiflow: Patients receive a single Lipiflow-treatment'}, {'id': 'OG002', 'title': 'Cross-over Lipiflow', 'description': 'Patients receive Lipiflow after performing Lid hygiene for 3 month'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '44.1', 'spread': '7.9', 'groupId': 'OG000'}, {'value': '43.4', 'spread': '9.9', 'groupId': 'OG001'}, {'value': '45.8', 'spread': '21.8', 'groupId': 'OG002'}]}]}, {'title': 'After 3 month', 'categories': [{'measurements': [{'value': '46.4', 'spread': '20.8', 'groupId': 'OG000'}, {'value': '47.4', 'spread': '16.7', 'groupId': 'OG001'}, {'value': '59.2', 'spread': '26.3', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'after 3 month compared to baseline value', 'description': 'lipid layer thickness (LLT) is measured with the Lipiview-interferometer;\n\nHigh values of LLT indicate a better lubrication of the ocular surface, so an increase in LLT can be regarded in an improvement of ocular surface.\n\nLLT is measured in Interferometric color units (ICUs) whereas 1 ICU reflects about 1 nm lipid layer thickness.', 'unitOfMeasure': 'nm', 'dispersionType': 'Standard Deviation'}, {'type': 'SECONDARY', 'title': 'Change in Expressible Meibomian Glands', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '17', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Standard Lid Hygiene Regime', 'description': 'Patients receive detailed verbal and written instruction to perform lid hygiene twice daily\n\nLid hygiene regime: Patients receive verbal and written instruction to perform lid hygiene twice daily'}, {'id': 'OG001', 'title': 'Lipiflow', 'description': 'Patients receive a singe Lipiflow-treatment\n\nLipiflow: Patients receive a single Lipiflow-treatment'}, {'id': 'OG002', 'title': 'Cross-over Lipiflow', 'description': 'Patients receive Lipiflow after performing Lid hygiene for 3 month'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '2.1', 'spread': '1.3', 'groupId': 'OG000'}, {'value': '2.5', 'spread': '1.4', 'groupId': 'OG001'}, {'value': '4.1', 'spread': '2.5', 'groupId': 'OG002'}]}]}, {'title': 'After 3 month', 'categories': [{'measurements': [{'value': '4.6', 'spread': '3.8', 'groupId': 'OG000'}, {'value': '5.5', 'spread': '3.6', 'groupId': 'OG001'}, {'value': '5.8', 'spread': '3.2', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'after 3 month compared to baseline value', 'description': 'expressible Meibomian glands are measured with the Meibomian gland evaluator; A higher number of expressible Meibomian glands indicate a lower likelihood Meibomian Gland dysfunction.', 'unitOfMeasure': 'number of expressible glands', 'dispersionType': 'Standard Deviation'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Standard Lid Hygiene Regime First, Then Lipiflow', 'description': 'Patients receive detailed verbal and written instruction to perform lid hygiene twice daily, then Lipiflow\n\nLid hygiene regime: Patients receive verbal and written instruction to perform lid hygiene twice daily and after 3 month a single Lipiflow treatment'}, {'id': 'FG001', 'title': 'Lipiflow', 'description': 'Patients receive a singe Lipiflow-treatment\n\nLipiflow: Patients receive a single Lipiflow-treatment'}], 'periods': [{'title': 'First Intervention', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '16'}, {'groupId': 'FG001', 'numSubjects': '19'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '14'}, {'groupId': 'FG001', 'numSubjects': '17'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '2'}]}], 'dropWithdraws': [{'type': 'Protocol Violation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '2'}]}]}, {'title': 'Cross-over', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '14'}, {'comment': 'Cross-over was only intended for the Lid margin hygiene group', 'groupId': 'FG001', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '9'}, {'comment': 'Was not intended by the study protocol', 'groupId': 'FG001', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '5'}, {'groupId': 'FG001', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '5'}, {'groupId': 'FG001', 'numSubjects': '0'}]}]}], 'preAssignmentDetails': 'Five patients had been enrolled in the study, but withdrew their participation after baseline examination for personal reasons. They did not receive any treatment.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'BG000'}, {'value': '17', 'groupId': 'BG001'}, {'value': '31', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Standard Lid Hygiene Regime First, Then Lipiflow', 'description': 'Patients receive detailed verbal and written instruction to perform lid hygiene twice daily, then Lipiflow\n\nLid hygiene regime: Patients receive verbal and written instruction to perform lid hygiene twice daily, then a single Lipiflow-treatment'}, {'id': 'BG001', 'title': 'Lipiflow', 'description': 'Patients receive a singe Lipiflow-treatment\n\nLipiflow: Patients receive a single Lipiflow-treatment'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '50', 'spread': '19', 'groupId': 'BG000'}, {'value': '45', 'spread': '23', 'groupId': 'BG001'}, {'value': '47', 'spread': '21', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '10', 'groupId': 'BG000'}, {'value': '12', 'groupId': 'BG001'}, {'value': '22', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '4', 'groupId': 'BG000'}, {'value': '5', 'groupId': 'BG001'}, {'value': '9', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'Germany', 'categories': [{'measurements': [{'value': '14', 'groupId': 'BG000'}, {'value': '17', 'groupId': 'BG001'}, {'value': '31', 'groupId': 'BG002'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'CROSSOVER'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 40}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2012-04'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2014-10', 'completionDateStruct': {'date': '2013-06', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2014-10-06', 'studyFirstSubmitDate': '2013-01-11', 'resultsFirstSubmitDate': '2014-09-01', 'studyFirstSubmitQcDate': '2013-01-15', 'lastUpdatePostDateStruct': {'date': '2014-10-07', 'type': 'ESTIMATED'}, 'resultsFirstSubmitQcDate': '2014-10-06', 'studyFirstPostDateStruct': {'date': '2013-01-16', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2014-10-07', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2013-06', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change of Dry Eye Symptoms', 'timeFrame': 'after 3 month compared to baseline value', 'description': 'The symptoms of dry eyes are measured in our study with the OSDI and the SPEED questionaire. Primary outcome measure (OSDI)\n\nPatients completed two symptom questionnaires: OSDI (Ocular Surface Disease Index) and SPEED (Standard Patient Evaluation of Eye dryness).\n\nOSDI scores range from 0 (no symptoms) to 100 (severe symptoms). SPEED scores range from 0 (no symptoms) to 28 (severe symptoms). So a reduction of the OSDI or SPEED score indicates an improvement of subjective dry eye symptoms.'}], 'secondaryOutcomes': [{'measure': 'Change of Break-up-time', 'timeFrame': 'after 3 month compared to baseline value', 'description': 'break-up-time is measured non-invasive with the Oculus Keratograph 5 M;\n\nThe break-up-time is measured in seconds. A low break-up-time suggests a lower lipid layer thickness. A higher break-up-time can be regarded as an improvement of ocular surface lubrication.'}, {'measure': 'Change in Tear Film Osmolarity', 'timeFrame': 'after 3 month compared to baseline value', 'description': 'osmolarity is measured with the tear-lab;\n\nThe osmolarity is measured in mOsm/l. A higher osmolarity can be regarded as an objective sign of dry eye disease.\n\nA lower osmolarity after therapy can be regarded as an improvement of ocular surface disease.'}, {'measure': 'Change in Lipid Layer Thickness', 'timeFrame': 'after 3 month compared to baseline value', 'description': 'lipid layer thickness (LLT) is measured with the Lipiview-interferometer;\n\nHigh values of LLT indicate a better lubrication of the ocular surface, so an increase in LLT can be regarded in an improvement of ocular surface.\n\nLLT is measured in Interferometric color units (ICUs) whereas 1 ICU reflects about 1 nm lipid layer thickness.'}, {'measure': 'Change in Expressible Meibomian Glands', 'timeFrame': 'after 3 month compared to baseline value', 'description': 'expressible Meibomian glands are measured with the Meibomian gland evaluator; A higher number of expressible Meibomian glands indicate a lower likelihood Meibomian Gland dysfunction.'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['Meibomian Gland Dysfunction', 'Lipiflow'], 'conditions': ['Meibomian Gland Dysfunction']}, 'referencesModule': {'references': [{'pmid': '24725326', 'type': 'RESULT', 'citation': 'Finis D, Hayajneh J, Konig C, Borrelli M, Schrader S, Geerling G. Evaluation of an automated thermodynamic treatment (LipiFlow(R)) system for meibomian gland dysfunction: a prospective, randomized, observer-masked trial. Ocul Surf. 2014 Apr;12(2):146-54. doi: 10.1016/j.jtos.2013.12.001. Epub 2014 Jan 22.'}]}, 'descriptionModule': {'briefSummary': 'Recently, beneficial effects on Meibomian gland dysfunction (MGD) of a single automated thermal pulsation with the Lipiflow® system have been reported in several case reports. In one study this treatment was compared with hyperthermia (iheat®) for 4 weeks. However, treatment recommendations for lid hygiene according to the MGD-report consist of hyperthermia followed by lid massage and lid margin cleansing over several months. To the best of the investigators knowledge this is the first randomized prospective study to compare automated thermal pulsation treatment with the new Lipiflow ® system with a standard lid hygiene regime.\n\nThe investigators suggest that a single treatment with Lipiflow® is superior to a lid hygiene regime.', 'detailedDescription': "Once a patient has been identified as a possible candidate for the study, he/she is first informed verbally and in writing about the study. After signing the consent form he/she will be randomized to either the Lipiflow® treatment (Lipiflow® group) or alternatively be given an instruction sheet and a verbal explanation for lid warming and massage (lid hygiene group). After 3 month a cross-over of the lid hygiene group to the Lipiflow® group is conducted.\n\nA full examination is performed before and 4 weeks and 3 months after therapy. All tests are performed by a physician or trained graduate students of the Department of Ophthalmology, Heinrich-Heine University. The examiner is blinded, i.e. he does not know which treatment the patient will receive or receiving.\n\nTreatment Lipiflow®:\n\nThe automated thermal pulsation with Lipiflow® provides is a low risk therapy. After local anesthesia the applicators are inserted. These look like a kind of goggles and consist of two parts which embrace the eyelids from the front and from behind. Through the rear part heat is applied to a maximum of 42.5° C. By isolating the heat remains on the eyelid limited. Through the front part the gland a massage is performed. The treatment takes 12 minutes per eye and can be done depending on the patient's wishes simultaneously or one eye after the other. The therapy is approved by the FDA as a medical technical innovation and has also been approved by ISO and CE Mark certification for use in Europe. Irritation or minor trauma of the eyelids and the conjunctiva and cornea, as well as a violation of the eyelids and the conjunctiva and cornea are theoretically possible, but extremely unlikely. Permanent damages to the eyes have not been reported in the literature.\n\nIn the unlikely event, that complications occur during treatment, requiring an additional treatment, this is performed in the department of ophthalmology of the Heinrich-Heine University Duesseldorf.\n\nTest parameters:\n\nAt any time of investigation, the following parameters are evaluated:\n\nLipiview®, Tear Lab®, Schirmer test, break-up time, corneal and conjunctival fluorescein staining, Meibomian gland evaluation (MGE), examination of the eyelids, Meibography, OSDI score, SPEED score\n\nAll test parameters are established procedures and have in common a very low risk of harm to the patient. In detail:\n\nThe Lipiview® is a device that quantifies the thickness of the lipid layer of the tear film using interferometry. For this the patient looks into a kind of camera while recordings of his tear film are made, which are then analyzed by a computer.\n\nTear Lab® is a method for measuring tear film osmolarity. A pen-like instrument (the osmometer) is held on the tear meniscus and collects 100 nl tears within fractions of a second in the unit. There is no need for local anaesthesia. By electrical impedance measurement, then the tear film osmolarity is measured. The examiner can then read the values digitally.\n\nThe Schirmer test consists of a strip of filter paper that is placed in the conjunctival sac of the patient for five minutes. The filter paper absorbs the tear fluid and the stained by the tear fluid line serves as a measure of tear secretion.\n\nTear break-up time is the time between a blink and the tear film shows signs of breaking up. In this study this is measured non-invasive with the Oculus-Keratograph 5 M®. The patient looks into a kind of camera while recordings of his tear film are made which are then analyzed by a computer.\n\nVital corneal and conjunctival epithelium cannot be stained by fluorescein. The dye adheres to nonviable cells. The degree of staining, can be judged by the investigator by slit-lamp examination.\n\nFor evaluation of the secreting meibomian glands a specialized device (Meibomian gland evaluator) is used, that provides a defined pressure to the lid. The examiner observes the ducts of the Meibomian glands and assesses how many glands are yielding secretion.\n\nExamination of the eyelids is done using a slit lamp to assess a thickening or a significant vascularisation the lid margin.\n\nTo perform meibography the lids are illuminated by infrared light. Functional acini of the glands become clearly visible and can be differentiated from atrophic acini. The number of atrophic meibomian glands can be counted by a score.\n\nOSDI (Ocular-Surface-Disease-Index) and SPEED (Standard Pattern Evaluation of Eye Dryness) are questionnaires to quantify the symptoms of dry eye."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* All patients with meibomian gland dysfunction requiring treatment (defined below),\n* who have given their written consent to the study.\n* Meibomian gland dysfunction requiring treatment is classified by us as:\n* Speed score\\> 7, Lipiview \\<61 nm, MGE \\<5 of 15 open glands\n\nExclusion Criteria:\n\n* Excluded are patients who, due to other diseases would not be able to fulfill the follow-up appointments or give an informed consent to the study\n* Systemic medication with tetracyclin derivatives, antihistamines, isotretinoin, or nutritional supplements for MGD that started \\<3 months before baseline examination\n* Topical cyclosporine-A or steroids that started \\<1 month before baseline examination\n* Ocular surgery or trauma \\<3 months before baseline examination\n* Any eyelid abnormalities\n* Systemic diseases resulting in dry eye.'}, 'identificationModule': {'nctId': 'NCT01769105', 'briefTitle': 'Comparison of Lipiflow®-Treatment and a Standard Lid Hygiene Regime', 'organization': {'class': 'OTHER', 'fullName': 'Heinrich-Heine University, Duesseldorf'}, 'officialTitle': 'Prospective, Randomized, Controlled Comparison of an Automated Thermal Pulsation Treatment (Lipiflow ®) and a Standard Lid Hygiene Regime', 'orgStudyIdInfo': {'id': 'HHUAU052012'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'Standard Lid Hygiene Regime', 'description': 'Patients receive detailed verbal and written instruction to perform lid hygiene twice daily', 'interventionNames': ['Behavioral: Lid hygiene regime']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Lipiflow', 'description': 'Patients receive a singe Lipiflow-treatment', 'interventionNames': ['Device: Lipiflow']}], 'interventions': [{'name': 'Lipiflow', 'type': 'DEVICE', 'description': 'Patients receive a single Lipiflow-treatment', 'armGroupLabels': ['Lipiflow']}, {'name': 'Lid hygiene regime', 'type': 'BEHAVIORAL', 'description': 'Patients receive verbal and written instruction to perform lid hygiene twice daily', 'armGroupLabels': ['Standard Lid Hygiene Regime']}]}, 'contactsLocationsModule': {'locations': [{'zip': 'D-40225', 'city': 'Düsseldorf', 'country': 'Germany', 'facility': 'Deparment of ophthalmology, Heinrich-Heine-University', 'geoPoint': {'lat': 51.22172, 'lon': 6.77616}}], 'overallOfficials': [{'name': 'Gerd Geerling, M.D.', 'role': 'STUDY_CHAIR', 'affiliation': 'Deparmtent of ophthalmology, Heinrich-Heine-University, Duesseldorf'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Heinrich-Heine University, Duesseldorf', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Principal investigator, department of ophthalmology', 'investigatorFullName': 'David Finis, MD', 'investigatorAffiliation': 'Heinrich-Heine University, Duesseldorf'}}}}